These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 17487784

  • 21. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
    Mocellin S, Nitti D.
    Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
    [Abstract] [Full Text] [Related]

  • 22. Potency assays for therapeutic live whole cell cancer vaccines.
    Petricciani J, Egan W, Vicari G, Furesz J, Schild G.
    Biologicals; 2007 Apr; 35(2):107-13. PubMed ID: 16882459
    [Abstract] [Full Text] [Related]

  • 23. Dendritic cell-based vaccination against cancer.
    Saito H, Frleta D, Dubsky P, Palucka AK.
    Hematol Oncol Clin North Am; 2006 Jun; 20(3):689-710. PubMed ID: 16762730
    [Abstract] [Full Text] [Related]

  • 24. Novel strategies for improved cancer vaccines.
    Chen X, Chang CH, Goldenberg DM.
    Expert Rev Vaccines; 2009 May; 8(5):567-76. PubMed ID: 19397414
    [Abstract] [Full Text] [Related]

  • 25. Advances in specific immunotherapy for prostate cancer.
    Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M.
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [Abstract] [Full Text] [Related]

  • 26. Vaccine immunotherapy in breast cancer treatment: promising, but still early.
    Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A.
    Expert Rev Anticancer Ther; 2007 Sep; 7(9):1225-41. PubMed ID: 17892423
    [Abstract] [Full Text] [Related]

  • 27. Cancer vaccines: between the idea and the reality.
    Finn OJ.
    Nat Rev Immunol; 2003 Aug; 3(8):630-41. PubMed ID: 12974478
    [Abstract] [Full Text] [Related]

  • 28. From genomics to cancer vaccines: patient-tailored or universal vaccines?
    Nadler LM, Schultze JL.
    Curr Opin Mol Ther; 2002 Dec; 4(6):572-6. PubMed ID: 12596359
    [Abstract] [Full Text] [Related]

  • 29. Technology Insight: vaccine therapy for prostate cancer.
    Vieweg J, Dannull J.
    Nat Clin Pract Urol; 2005 Jan; 2(1):44-51. PubMed ID: 16474576
    [Abstract] [Full Text] [Related]

  • 30. Discovery and development of therapeutic cancer vaccines.
    Acres B, Limacher JM, Bonnefoy J.
    Curr Opin Drug Discov Devel; 2007 Mar; 10(2):185-92. PubMed ID: 17436554
    [Abstract] [Full Text] [Related]

  • 31. Heat shock proteins as vaccine adjuvants in infections and cancer.
    Segal BH, Wang XY, Dennis CG, Youn R, Repasky EA, Manjili MH, Subjeck JR.
    Drug Discov Today; 2006 Jun; 11(11-12):534-40. PubMed ID: 16713905
    [Abstract] [Full Text] [Related]

  • 32. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC, Chen W, Ohlfest JR.
    J Immunother; 2007 Jun; 30(8):789-97. PubMed ID: 18049330
    [Abstract] [Full Text] [Related]

  • 33. Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome.
    Slovin SF.
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):972-80. PubMed ID: 18277959
    [Abstract] [Full Text] [Related]

  • 34. Breast cancer vaccines: promise for the future or pipe dream?
    Mittendorf EA, Peoples GE, Singletary SE.
    Cancer; 2007 Oct 15; 110(8):1677-86. PubMed ID: 17763371
    [Abstract] [Full Text] [Related]

  • 35. Dendritic cell-based cancer vaccination: quo vadis?
    Dauer M, Schnurr M, Eigler A.
    Expert Rev Vaccines; 2008 Sep 15; 7(7):1041-53. PubMed ID: 18767953
    [Abstract] [Full Text] [Related]

  • 36. Type I interferons as vaccine adjuvants against infectious diseases and cancer.
    Bracci L, La Sorsa V, Belardelli F, Proietti E.
    Expert Rev Vaccines; 2008 Apr 15; 7(3):373-81. PubMed ID: 18393607
    [Abstract] [Full Text] [Related]

  • 37. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
    Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R.
    J Clin Oncol; 2007 Aug 20; 25(24):3680-7. PubMed ID: 17704416
    [Abstract] [Full Text] [Related]

  • 38. Outlining novel cellular adjuvant products for therapeutic vaccines against cancer.
    Tefit JN, Serra V.
    Expert Rev Vaccines; 2011 Aug 20; 10(8):1207-20. PubMed ID: 21854313
    [Abstract] [Full Text] [Related]

  • 39. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL.
    Ann N Y Acad Sci; 2009 Sep 20; 1174():107-17. PubMed ID: 19769743
    [Abstract] [Full Text] [Related]

  • 40. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, Punt CJ.
    Crit Rev Oncol Hematol; 2008 May 20; 66(2):118-34. PubMed ID: 18262431
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.